Outcome data were measured at baseline, 6, 12 and 18 months of intervention.
The content of n-3 PUFA in serum phospholipids and homocysteine levels in plasma were measured at baseline and after 3 months of intervention.
After 6 months of intervention, 83 subjects in the intervention group and 182 subjects in the control group had completed the study.
Meanwhile, the proportion of patients with an abnormal BP rate decreased from 20.5% in the initial month of the study to 10.9% after 3 10 months of intervention.
After six months of intervention and six months of follow up, interim analysis showed the algorithm-generated diets were able to significantly reduce (by 60%) blood glucose when compared to participants' habitual diets.
Little evidence is available on the longer-term effects (beyond 12 months) of intervention models consisting of hip fracture-specific care in conjunction with management of malnutrition, depression, and falls.
Anthropometric parameters, cardiorespiratory capacity, glycemic and lipid profile, apolipoprotein (apo) A-I, apo B, interleukin (IL -10, IL -10 insulin resinsulin, and blood presistancere meandred bloode and after 12 months of intervention (pressure
Participants with comorbid panic disorder showed similar outcomes, whereas those with comorbid PTSD showed a more delayed response, requiring 12 months of intervention to show a significant effect.
Hcy levels did not significantly decrease in the treatment group compared to the placebo group after 6 months of intervention *P values were determined by t-test.
For the blood biochemistries at follow-up (Table 2) - folate, B6 and B12 levels were significantly higher in the treatment group compared to placebo group (P < 0.0001) after 6 months of intervention.
Plasma homocysteine levels remained at 9.5 μmol/l for the placebo group while in the treatment group, plasma homocysteine levels decreased from 9.4 to 8.5 μmol/l after the 6 months of intervention.
